What is Zynerba Pharmaceuticals?
Headquartered in Devon, Pennsylvania, Zynerba Pharmaceuticals operates as a specialty pharmaceutical entity dedicated to the research and development of pharmaceutically-produced transdermal cannabinoid therapies. Originally established as AllTranz, Inc. in 2007, the company rebranded in 2014 to better reflect its focus on neuropsychiatric conditions. Its core asset, Zygel, utilizes a permeation-enhanced gel technology designed for transdermal delivery, offering a distinct pharmacological profile compared to traditional oral or inhaled delivery methods. By targeting specific patient populations with limited treatment options, Zynerba occupies a high-barrier-to-entry niche within the broader life sciences market, leveraging its intellectual property to navigate the complex regulatory landscape of cannabinoid-based medicine.
How much funding has Zynerba Pharmaceuticals raised?
Zynerba Pharmaceuticals has raised a total of $149.2M across 4 funding rounds:
Unspecified
$13M
Stock Offering
$48.3M
Stock Offering
$58M
Stock Offering
$29.9M
Unspecified (2014): $13M with participation from Perceptive Advisors
Stock Issuance/Offering (2015): $48.3M led by Undisclosed
Stock Issuance/Offering (2017): $58M supported by Undisclosed
Stock Issuance/Offering (2018): $29.9M featuring Undisclosed
Key Investors in Zynerba Pharmaceuticals
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
Undisclosed Investors
Undisclosed Investors
What's next for Zynerba Pharmaceuticals?
With the successful procurement of $29.9M, Zynerba Pharmaceuticals is well-positioned to scale its clinical operations and advance its pipeline through critical regulatory phases. The strategic deployment of this capital will likely focus on expanding the clinical trial footprint for Zygel, optimizing manufacturing processes for large-scale production, and strengthening the company's commercialization strategy. As the firm transitions toward potential market entry, the focus will shift from early-stage research to late-stage clinical validation and market access preparation. Investors will be closely monitoring the company's ability to meet primary endpoints in ongoing trials, which will serve as the primary catalyst for future valuation growth and potential strategic partnerships within the pharmaceutical industry.
See full Zynerba Pharmaceuticals company page
